IQVIA Posts Strong Q1 2026 Growth, Raises EPS Guidance
Event summary
- IQVIA reported Q1 2026 revenue of $4.15 billion, up 8.4% year-over-year.
- Commercial Solutions revenue grew 11.6%, driven by AI-enabled offerings.
- R&D Solutions revenue increased 6.2%, with a $34.2 billion contracted backlog.
- Adjusted Diluted EPS of $2.90 exceeded expectations, up 7.4% year-over-year.
- Company raised full-year 2026 EPS guidance to $12.65–$12.95.
The big picture
IQVIA's Q1 2026 results reflect strong demand for its AI-driven solutions and clinical research services. The company's strategic shift to a simplified organizational model aims to enhance efficiency and support continued growth. With a robust backlog and raised EPS guidance, IQVIA is positioning itself to capitalize on the evolving needs of the life sciences and healthcare industries.
What we're watching
- AI Adoption
- How IQVIA's AI-enabled offerings will sustain growth in Commercial Solutions.
- Market Stability
- Whether mid-to-high single-digit growth in R&D demand indicators will persist.
- Debt Management
- The pace at which IQVIA reduces its net debt of $13.89 billion.
Related topics